Wasatch Advisors LP Trims Holdings in AtriCure, Inc. $ATRC

Wasatch Advisors LP decreased its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 28.2% in the first quarter, HoldingsChannel reports. The firm owned 253,931 shares of the medical device company’s stock after selling 99,946 shares during the quarter. Wasatch Advisors LP’s holdings in AtriCure were worth $7,245,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Aster Capital Management DIFC Ltd increased its holdings in AtriCure by 197.1% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company’s stock worth $29,000 after buying an additional 538 shares during the period. Geneos Wealth Management Inc. acquired a new stake in AtriCure during the 2nd quarter valued at approximately $37,000. Smartleaf Asset Management LLC lifted its stake in AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after acquiring an additional 429 shares during the period. Global Retirement Partners LLC purchased a new stake in shares of AtriCure in the 4th quarter valued at $73,000. Finally, State of Wyoming purchased a new stake in shares of AtriCure in the 4th quarter valued at $75,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Stock Performance

Shares of NASDAQ ATRC opened at $30.18 on Friday. The company’s fifty day moving average price is $28.00 and its 200 day moving average price is $32.45. AtriCure, Inc. has a 1 year low of $25.36 and a 1 year high of $43.18. The company has a market capitalization of $1.53 billion, a PE ratio of -301.80 and a beta of 1.26. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.18 and a current ratio of 4.29.

Insiders Place Their Bets

In other AtriCure news, Director Karen Prange sold 3,000 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total value of $85,950.00. Following the completion of the transaction, the director owned 26,373 shares in the company, valued at approximately $755,586.45. This represents a 10.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Freedom Capital upgraded shares of AtriCure to a “strong-buy” rating in a research note on Wednesday, April 1st. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 4th. Weiss Ratings lowered shares of AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 4th. Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Canaccord Genuity Group lifted their price objective on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $48.71.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.